Andere Sprachen XTL Biopharmaceuticals Ltd. Nasdaq

Aktien

A2DK34

US98386D3070

XTLB

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 21.05.2024			% 5 Tage	% 1. Jan.
2.8 ^USD	+7.69%		+8.95%	+177.20%

30.04.	XTL Biopharmaceuticals Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
29.04.	Top-Zuwächse vorbörslich	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	30.04.
Top Premarket Gainers	29.04.
XTL Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K	02.04.
XTL Biopharmaceuticals : Immediate Report of Meeting	21.03.
XTL Biopharmaceuticals : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 - Form 6-K	21.03.
XTL Biopharmaceuticals Ltd. announced that it expects to receive $1.5 million in funding	20.03.
Top Midday Gainers	20.03.
XTL Biopharmaceuticals to Acquire The Social Proxy; Shares Soar	20.03.
XTL To Aquire The Social Proxy	20.03.
XTL Biopharmaceuticals Ltd. entered into a binding term sheet to acquire THE SOCIAL PROXY Ltd.	20.03.
XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	15.11.
XTL Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K	15.11.
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	20.10.23
XTL Biopharmaceuticals : OPERATING AND FINANCIAL REVIEW AND PROSPECTS (Form 6-K)	25.08.21
XTL Biopharmaceuticals Ltd. Elects Alexander Rabinovitch as Directors	03.08.17
XTL Biopharmaceuticals Appoints Alex Rabinovich to its Board of Directors	27.04.17
XTL Biopharmaceuticals Ltd. Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome	05.04.17
XTL Biopharmaceuticals Ltd. Announces Resignation David Kestenbaum as Chief Financial Officer	04.04.17
XTL Biopharmaceuticals Ltd. Reports Audited Consolidated Earnings Results for the Full Year Ended December 31, 2016	30.03.17
XTL Biopharmaceuticals Ltd. announced that it has received $2.8 million in funding	22.03.17

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen XTL Biopharmaceuticals Ltd. Nasdaq

Aktien

A2DK34

US98386D3070

XTLB

Andere Sprachen

Filter